GM-CSF + aldesleukin + docetaxel + gemcitabine

This is a multi-agent combination therapy consisting of four drugs: - **Granulocyte-macrophage colony-stimulating factor (GM-CSF):** A cytokine that stimulates the production and function of white blood cells, particularly granulocytes and macrophages. It acts primarily by binding to the GM-CSF receptor on myeloid cells, promoting their proliferation, differentiation, and activation. In cancer therapy, it can enhance immune responses against tumors by activating dendritic cells and macrophages[5][9]. - **Aldesleukin (interleukin-2 or IL-2):** A recombinant form of human interleukin 2 that stimulates the growth and activity of T lymphocytes and natural killer (NK) cells. It is used as an immunotherapy agent in certain cancers to boost antitumor immune responses[1][10]. - **Docetaxel:** A cytotoxic small molecule chemotherapeutic agent from the taxane class that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing tumor cells[7][10]. - **Gemcitabine:** A nucleoside analog antimetabolite chemotherapy drug that inhibits DNA synthesis by incorporating into DNA strands during replication, resulting in cell death[10]. The rationale for combining these agents is to leverage both direct cytotoxic effects on tumor cells (docetaxel/gemcitabine) with enhanced immune-mediated antitumor activity via cytokines (GM-CSF/aldesleukin). Clinical studies have evaluated this combination or similar regimens as second-line treatment for advanced non-small-cell lung cancer (NSCLC), showing promising response rates when cytokines are added to chemotherapy[10].

Other names

granulocyte-macrophage colony-stimulating factor + interleukin-2 + docetaxel + gemcitabineGM-CSF + IL-2 (aldesleukin) + docetaxel + gemcitabine